New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists
Rüdiger HardelandJohann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, GermanyAbstract: Hypnotic effects of melatonin and melatoninergic drugs are mediated via MT1 and MT2 receptors, especially those in the circadian pacemaker, the supr...
Guardado en:
Autor principal: | Rüdiger Hardeland |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9b9a496c718a49db815df23f71ba42d1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study
por: Garfinkel D, et al.
Publicado: (2011) -
Insomnia and somnolence in idiopathic RBD: a prospective cohort study
por: Ronald B. Postuma, et al.
Publicado: (2017) -
The societal costs of insomnia
por: Alan G Wade
Publicado: (2010) -
Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series
por: Meghan Humbert, et al.
Publicado: (2017) -
Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
por: Jan K Buitelaar, et al.
Publicado: (2009)